Abstract
Nowadays we have a number of chemical and biological agents at our disposal to treat chronic pathologies such as cancer. Although most drugs display significant activity, thus improving the clinical outcome, side-effects and emergence of resistances cannot be looked down. From an historical point of view, higher plants have been very important in the search of new therapeutic agents and they were in the origin of the first medicines used in human health. The contribute of plants to treat pathologies such as cancer is far from being over, mainly due to the high number of new drugs that are currently being evaluated in clinical trials. Metabolomics-based studies have rendered several new chemical entities, some of them with remarkable complex chemistry, which sometimes results in novel mechanisms of action, higher potency and lower toxicity. In this review, we will focus the most important plant-derived classes of compounds in clinical use, as well as those currently in clinical trials, with special focus on vinca alkaloids, taxanes, combretastatins, podophylotoxins and camptothecins. The molecular mechanism of action and spectrum of activity will also be discussed.
Keywords: Cancer, plants secondary metabolites, vinca alkaloids, taxanes, combretastatins, podophylotoxins and camptothecins, Cancer Chemotherapy, Metabolomics-based studies, toxicity, codeine, digitoxin, morphine, vincristine
Current Pharmaceutical Biotechnology
Title:Plant Secondary Metabolites in Cancer Chemotherapy: Where are We?
Volume: 13 Issue: 5
Author(s): David M. Pereira, Patricia Valentao, Georgina Correia-da-Silva, Natercia Teixeira, Paula B. Andrade
Affiliation:
Keywords: Cancer, plants secondary metabolites, vinca alkaloids, taxanes, combretastatins, podophylotoxins and camptothecins, Cancer Chemotherapy, Metabolomics-based studies, toxicity, codeine, digitoxin, morphine, vincristine
Abstract:
Nowadays we have a number of chemical and biological agents at our disposal to treat chronic pathologies such as cancer. Although most drugs display significant activity, thus improving the clinical outcome, side-effects and emergence of resistances cannot be looked down. From an historical point of view, higher plants have been very important in the search of new therapeutic agents and they were in the origin of the first medicines used in human health. The contribute of plants to treat pathologies such as cancer is far from being over, mainly due to the high number of new drugs that are currently being evaluated in clinical trials. Metabolomics-based studies have rendered several new chemical entities, some of them with remarkable complex chemistry, which sometimes results in novel mechanisms of action, higher potency and lower toxicity. In this review, we will focus the most important plant-derived classes of compounds in clinical use, as well as those currently in clinical trials, with special focus on vinca alkaloids, taxanes, combretastatins, podophylotoxins and camptothecins. The molecular mechanism of action and spectrum of activity will also be discussed.
Export Options
About this article
Cite this article as:
David M. Pereira, Patricia Valentao, Georgina Correia-da-Silva, Natercia Teixeira, Paula B. Andrade , Plant Secondary Metabolites in Cancer Chemotherapy: Where are We?, Current Pharmaceutical Biotechnology 2012; 13 (5) . https://dx.doi.org/10.2174/138920112799857530
DOI https://dx.doi.org/10.2174/138920112799857530 |
Print ISSN 1389-2010 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4316 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Emerging RNA-based Drugs: siRNAs, microRNAs and Derivates
Central Nervous System Agents in Medicinal Chemistry Clinical Pharmacology of Serotonin Receptor Type 3 (5-HT3) Antagonists
Current Medicinal Chemistry - Central Nervous System Agents MSIT: Malonylation Sites Identification Tree
Current Bioinformatics Fibroblast Growth Factor-Inducible 14: Multiple Roles in Tumor Metastasis
Current Molecular Medicine Anti-Cancer Stem Cells Potentiality of an Anti-Malarial Agent Quinacrine: An Old Wine in a New Bottle
Anti-Cancer Agents in Medicinal Chemistry Cytotoxicity and Chemotherapeutic Potential of Natural Rosin Abietane Diterpenoids and their Synthetic Derivatives
Current Pharmaceutical Design Nanoparticle-based Drug Delivery Systems for Targeted Epigenetics Cancer Therapy
Current Drug Targets Withdrawal Notice: Drug Repurposing for Prospective Anti-Cancer Agents Along with the Clinical Status of the Repurposed Drug
Anti-Cancer Agents in Medicinal Chemistry HPV Infection and Intraepithelial Lesions: Comparison Between HIVPositive and Negative Women
Current HIV Research (Iso)Flav(an)ones, Chalcones, Catechins, and Theaflavins as Anticarcinogens: Mechanisms, Anti-Multidrug Resistance and QSAR Studies
Current Medicinal Chemistry Comparative Analysis of Current Modality of Therapy in Head and Neck Squamous Cell Carcinoma Correlating the Expression Level of p38α
Current Cancer Therapy Reviews Role of Glioma-associated GLI1 Oncogene in Carcinogenesis and Cancertargeted Therapy
Current Cancer Drug Targets Angiogenesis Inhibitors: Perspectives for Medical, Surgical and Radiation Oncology
Current Pharmaceutical Design Pre-therapy Iodine-131 Uptake Value as a Prediction Method for Metastatic Lymph Node Status in Patients with Differentiated Thyroid Carcinoma
Current Medical Imaging Recent Developments Towards the Synthesis of Varitriol: An Antitumour Agent from Marine Derived Fungus Emericella Variecolor
Current Organic Synthesis New Molecular Targets of Anticancer Therapy – Current Status and Perspectives
Current Medicinal Chemistry PET and SPECT Imaging of Tumor Biology: New Approaches Towards Oncology Drug Discovery and Development
Current Computer-Aided Drug Design Diverse Roles of GADD45α in Stress Signaling
Current Protein & Peptide Science Research Progress of PARP Inhibitor Monotherapy and Combination Therapy for Endometrial Cancer
Current Drug Targets Intervening Stemness and Angiogenesis in Cervical Carcinoma: Revisiting the Efficacy of Natural Compounds
Endocrine, Metabolic & Immune Disorders - Drug Targets